Jun. 3 at 12:32 PM
$PEPG Chart update: Stock continues to fail at the EMA 50 -- another rejection at overhead resistance keeps the downtrend intact. S-1 support at
$1.18 is back in play, with S-2 at
$0.88 marking the 52-week low. A sustained break of S-1 opens the door for a potential retest of that lower range.
For those unfamiliar, the co announced it's discontinuing its DMD program after PGN-EDO51 failed to show meaningful dystrophin expression in the CONNECT1 trial. With DMD now off the table, all attention shifts to the DM1 program, but that still carries clinical risk heading into key data later this year and into 2026. BofA also lowered its PT to
$1 on the back of the failed DMD results and ongoing uncertainty.
Given both the technical and fundamental setup, a move toward that S-2 level remains very possible if support doesn't hold. Stay tuned. JMHO. GLTA
